Rosetta Genomics announces two new patent allowances for microRNA technology
Rosetta Genomics said it has added two new patent allowances to its intellectual property portfolio for its microRNA platform technology. With these new allowances, Rosetta Genomics has 64 granted or allowed patents and 33 patents pending. Rosetta Genomics has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 12/999,201, entitled, "Compositions and Methods for Prognosis of Ovarian Cancer." The allowed patent claims a method of predicting progression of platinum-resistant stage III ovarian cancer in response to platinum-based chemotherapy, based on the expression of hsa-miR-27a in an ovarian tumor sample. The company also received a Notice of Allowance from the Korean Intellectual Property Office for Korean Patent Application No. 2010-7007495, entitled, "Diagnosis and Prognosis of Specific Cancers." The allowed patent claims a method for diagnosing pleural mesothelioma or distinguishing between pleural mesothelioma and other cancers, using the expression profile of hsa-miR-192, hsa-miR-200c and hsa-miR-193a. Corresponding U.S. Patent 9,133,522 has been granted in the U.S.